MedTrace Logo

Prazosin Augmentation of Outpatient Treatment of Alcohol Use Disorders in Active Duty Soldiers With and Without PTSD

NCT02226367 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 158

Last updated 2023-02-03

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to evaluate if the drug prazosin:

* will decrease alcohol use in active duty members of the military who served in Iraq and/or Afghanistan and
* determine if presence or absence of posttraumatic stress disorder affects treatment.

Conditions

  • Alcohol Use Disorders
  • Stress Disorders, Posttraumatic
  • Combat Disorders

Interventions

DRUG

prazosin hydrochloride

study drug arm prazosin

DRUG

placebo

study drug arm placebo

Sponsors & Collaborators

  • United States Department of Defense

    collaborator FED

  • VA Puget Sound Health Care System

    collaborator FED

  • Seattle Institute for Biomedical and Clinical Research

    lead OTHER

Principal Investigators

  • Murray Raskind, MD · Department of Veterans Affairs Puget Sound Health Care System

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2018-09-20
Completion
2018-10-20

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02226367 on ClinicalTrials.gov